Pulmonary Embolism News and Research

RSS

A pulmonary embolism is a sudden blockage in a lung artery. The cause is usually a blood clot in the leg called a deep vein thrombosis that breaks loose and travels through the bloodstream to the lung.

Current Medical Research & Opinion publishes new data on EVISTA for postmenopausal osteoporosis

Eli Lilly and Company today announced that data on EVISTA® (raloxifene HCl tablets) therapy for more than three years was published online in Current Medical Research & Opinion.

10 Aug 2011

Curis second quarter net loss increases to $4.9 million

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today reported its financial results for the second quarter ended June 30, 2011.

28 Jul 2011

Hip and knee replacement surgery linked to increased risk of clot development

When tennis star Serena Williams underwent emergency treatment for a pulmonary embolism earlier this year, the world's attention was drawn to this often fatal medical condition which, although surprisingly not uncommon, is unfamiliar to most men and women.

28 Jul 2011

VDF's annual meeting to discuss latest information in vascular disease

The Vascular Disease Foundation (VDF) is pleased to announce that Thomas R. Frieden, MD, MPH, Director, Centers for Disease Control and Prevention will be the keynote speaker at its annual meeting, "Current Issues in Vascular Disease" September 14-15 in McLean, VA.

28 Jul 2011

Baxter GAMMAGARD LIQUID for PI receives FDA approval for subcutaneous administration

Baxter International Inc. announced today that the U.S. Food and Drug Administration has approved the subcutaneous administration of GAMMAGARD LIQUID 10% [Immune Globulin Infusion (Human)] for patients with primary immunodeficiency.

From Baxter International Inc. 25 Jul 2011

Johnson & Johnson second quarter sales increase 8.3% to $16.6 billion

Johnson & Johnson today announced sales of $16.6 billion for the second quarter of 2011, an increase of 8.3% as compared to the second quarter of 2010.

19 Jul 2011

Six UC institutions to improve hospital care

A key component of health care reform involves the improvement of quality, access and value when delivering health services, particularly for patients admitted to a hospital. To help meet these needs, the University of California established the Center for Health Quality and Innovation, which provides financial support for health quality initiatives across the UC health system.

16 Jul 2011

ThromboView gets positive results in study evaluating accuracy and safety

Drug and diagnostic company Agenix Limited (ASX: AGX), today announced the positive results of a study to evaluate the efficacy and accuracy

7 Jul 2011

Study: Cancer patients with VTE do not benefit from IVCF and fondaparinux

Cancer patients with blood clots -- which occur in one of every 200 cancer patients and are the second most common cause of death among cancer patients -- gain no benefit from the insertion of an inferior vena cava filter (IVCF) to the anticoagulant medication fondaparinux (Arixtra), according to research presented today at the 14th World Conference on Lung Cancer, hosted by the International Association for the Study of Lung Cancer.

7 Jul 2011

Women with sedentary lifestyle more likely to develop pulmonary embolism

Women who sit for long periods of time everyday are two to three times more likely to develop a life-threatening blood clot in their lungs than more active women, finds a study published on bmj.com today.

5 Jul 2011

Fast track protocol reduces hospital costs and infections in total hip replacement surgery

Generally healthy patients who undergo total hip replacement (THR) can be fast tracked to be discharged in two days compared with the standard three to six days, according to a new study by researchers at Hospital for Special Surgery (HSS) in New York City. The study could help cut down on hospital-acquired infections, reduce hospital costs and improve patient satisfaction.

1 Jul 2011

Low-risk patients with pulmonary embolism can benefit from outpatient care

Outpatient care for certain low-risk patients with pulmonary embolism (PE) can be safely and effectively used in place of inpatient care, according to a randomized, multi-center study in 19 emergency departments.

24 Jun 2011

Celgene announces data from REVLIMID plus rituximab Phase II study on malignant lymphomas

Celgene International Sàrl announced that clinical data from a Phase II study, conducted by investigators from the MD Anderson Cancer Center in Houston, TX, evaluating the combination regimen of REVLIMID plus rituximab (R2) in untreated, advanced stage, indolent B-cell non-Hodgkin's lymphomas, were presented at the 11th International Conference on Malignant Lymphoma in Lugano, Switzerland.

18 Jun 2011

Celgene, GELA to conduct REVLIMID/rituximab combination study on newly diagnosed FL

Groupe d'Etude des Lymphomes de l'Adulte (GELA) and Celgene International Sarl today announced a collaboration to conduct an international randomized study to evaluate the therapeutic potential of the REVLIMID/rituximab combination regimen (R2) in patients with newly diagnosed follicular lymphoma.

17 Jun 2011

REVLIMID-R-CHOP Phase I/II data in untreated DLBCL presented at malignant lymphoma conference

Celgene International Sàrl announced that clinical data from two studies evaluating the use of REVLIMID® (lenalidomide) with standard R-CHOP chemotherapy in patients with untreated diffuse large B cell (DLBCL) or grade 3 follicular lymphoma were presented at the 11th International Conference on Malignant Lymphoma in Lugano, Switzerland.

17 Jun 2011

Study explores link between hospital procedure volume, surgical outcomes after joint replacements

Patients who undergo elective total hip or total knee arthroplasty at hospitals with lower surgical volume had a higher risk of venous thromboembolism and mortality following the procedure.

7 Jun 2011

Synta presents ganetespib Phase 1, 2 trial results against solid tumors at ASCO 2011

Synta Pharmaceuticals Corp. today presented results at the Annual Meeting of the American Society for Clinical Oncology (ASCO) from a Phase 2 single agent clinical trial of ganetespib in gastrointestinal stromal tumors (GIST) and a Phase 1 trial of ganetespib in solid tumors evaluating a twice-weekly administration schedule.

7 Jun 2011

Celgene announces results of REVLIMID, docetaxel/prednisone phase II combination study on mCRPC

Celgene International Sàrl today announced results from a phase II investigator initiated study of REVLIMID (lenalidomide) in combination with Avastin (bevacizumab), docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer were presented at the 2011 American Society of Clinical Oncology Annual Meeting in Chicago, Ill.

6 Jun 2011

Safety of birth control pills under scrutiny

Bayer’s oral contraceptive pills are being reviewed by regulators after some studies suggested they may cause more blood clots than competing medicines.

5 Jun 2011

Sanofi's semuloparin Phase III study data against venous thromboembolism presented at ASCO 2011

Sanofi US announced today results of the pivotal SAVE-ONCO study which demonstrated that, in cancer patients initiating a chemotherapy regimen, investigational semuloparin significantly reduced the risk of the composite of symptomatic-deep vein thromboembolism (DVT), non-fatal pulmonary embolism (PE) or venous thromboembolism (VTE)-related death by 64%, meeting the study primary endpoint.

4 Jun 2011

Pulmonary Embolism News and Research

Further Reading

Current Medical Research & Opinion publishes new data on EVISTA for postmenopausal osteoporosis

Curis second quarter net loss increases to $4.9 million

Hip and knee replacement surgery linked to increased risk of clot development

VDF's annual meeting to discuss latest information in vascular disease

Baxter GAMMAGARD LIQUID for PI receives FDA approval for subcutaneous administration

Johnson & Johnson second quarter sales increase 8.3% to $16.6 billion

Six UC institutions to improve hospital care

ThromboView gets positive results in study evaluating accuracy and safety

Study: Cancer patients with VTE do not benefit from IVCF and fondaparinux

Women with sedentary lifestyle more likely to develop pulmonary embolism

Fast track protocol reduces hospital costs and infections in total hip replacement surgery

Low-risk patients with pulmonary embolism can benefit from outpatient care

Celgene announces data from REVLIMID plus rituximab Phase II study on malignant lymphomas

Celgene, GELA to conduct REVLIMID/rituximab combination study on newly diagnosed FL

REVLIMID-R-CHOP Phase I/II data in untreated DLBCL presented at malignant lymphoma conference

Study explores link between hospital procedure volume, surgical outcomes after joint replacements

Synta presents ganetespib Phase 1, 2 trial results against solid tumors at ASCO 2011

Celgene announces results of REVLIMID, docetaxel/prednisone phase II combination study on mCRPC

Safety of birth control pills under scrutiny

Sanofi's semuloparin Phase III study data against venous thromboembolism presented at ASCO 2011

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News